About Us
About Guard Therapeutics Vision, mission & goal The Board Management
Research & Development
Acute kidney injury RMC-035 (ROSgard) Clinical development Patents
Investor Relations
Financial calender Financial reports Share information Corporate governance General meetings
News & Media
Press releases Event calender Analyses and presentations In media Subscribe
Contact
Swe
Search

Financial reports

Financial reports

Interim reports

2024

Interim report January-March 2024

Other financial reports are currently only available in Swedish.

Subscribe to our press releases

Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Mail Address

Guard Therapeutics AB
Box 5216
102 45 Stockholm, Sweden

Visiting Address

Guard Therapeutics
Nybrogatan 34, 2 tr
114 39 Stockholm, Sweden

Telephone

+46 (0)8 670 65 51

E-mail

info@guardtherapeutics.com

Follow us

LinkedIn

© GUARD THERAPEUTICS INTERNATIONAL AB 2024